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Introduction {#sec1}
============

Hematopoietic aging is characterized by expansion of hematopoietic stem cells (HSCs) with impaired function, such as reduced engraftment, quiescence, self-renewal, unfolded protein response, and lymphoid differentiation potential, leading to myeloid-biased output both in mice ([@bib32], [@bib40], [@bib51], [@bib56]) and humans ([@bib45], [@bib53]). Myeloid malignancies are more frequent in the elderly, but whether changes in the aged HSCs and/or their microenvironment predispose to these malignancies remains unclear. HSC aging was initially considered to result only from intrinsic changes ([@bib10]), such as epigenetic deregulation ([@bib4]), replication stress ([@bib15]), deficient DNA repair ([@bib52]), transition from canonical to non-canonical Wnt signaling ([@bib16]), and increased autophagy ([@bib24]). However, aging also reduces HSC polarity and capacity to lodge near bone ([@bib28]), and microenvironmental alterations have been proposed to contribute to hematopoietic aging. For instance, myeloid bias can result from telomere dysfunction ([@bib27]) or inflammatory cytokine production ([@bib12]) in the aged hematopoietic microenvironment, and bone marrow (BM) adrenergic nerve degeneration has been recently proposed to drive HSC aging reversibly ([@bib34]). However, the relative contribution of intrinsic and extrinsic mechanisms to HSC aging remains debated. Myeloid-biased HSCs ([@bib19]) and more prominently platelet-primed HSCs ([@bib54], [@bib61]) expand in aged mice ([@bib21]). However, both platelet-primed and unprimed old HSCs exhibit myeloid bias ([@bib21]), possibly suggesting a microenvironmental participation. The standard model of platelet generation (thrombopoiesis) suggests that megakaryocyte precursors migrate from endosteal BM (close to bone) to sinusoids (further from bone) for maturation ([@bib14]), which can be promoted by cytokines like interleukin (IL)-1α IL-1β, IL-6, IL-3, and interferon-gamma (IFNγ) ([@bib46]). Whereas platelet-biased HSCs are located near sinusoids ([@bib47]), both megakaryocytes and their precursors have been recently found throughout BM, including the sinusoids where megakaryocyte maturation and thrombopoiesis take place ([@bib49], [@bib55]). In this study, we have investigated whether different BM microenvironments regulate myeloid differentiation and megakaryopoiesis during aging.

Results {#sec2}
=======

Reduction of Endosteal Niches and Expansion of Non-endosteal Neurovascular Niches during Aging {#sec2.1}
----------------------------------------------------------------------------------------------

To characterize changes in vascular beds during aging, we performed whole-mount immunofluorescence staining of thick femoral sections of young and old wild type (WT) mice using CD31 and endomucin (EMCN) to identify sinusoids, arterioles, capillaries, and transition zone vessels (TZVs), which connect arterioles with sinusoids near bone (endosteum). Consistent with previous findings ([@bib30]), endosteal vessels and TZVs were reduced in old mice; however, we also noted that, whereas sinusoidal areas appeared unchanged, arterioles were slightly reduced and capillaries located further from bone increased 4-fold in old mice ([Figures 1](#fig1){ref-type="fig"}A--1F). These vascular changes were paralleled by similar alterations of their associated perivascular cells. We used *Nes-gfp* transgenic mice, which carry HSC niche-forming perivascular BM mesenchymal stem or progenitor cells (BMSCs) labeled with GFP ([@bib37]). Nes-GFP^+^ cells augmented 4-fold specifically in non-endosteal BM, mostly associated with the increased capillaries ([Figures 1](#fig1){ref-type="fig"}G--1I and [S1](#mmc1){ref-type="supplementary-material"}A--S1D). These changes correlated with increased inflammatory cytokines that drive myeloid cell expansion ([@bib46]). The concentration of IL-1α, IL-1β, and IL-6 increased in the BM during aging, whereas IL-3 and IFNγ showed similar trends ([Figures 1](#fig1){ref-type="fig"}J--1N and [S1](#mmc1){ref-type="supplementary-material"}M-S1Q).Figure 1Reduction of Endosteal Niches and Expansion of Non-endosteal Niches during Aging(A--B′ and H--I′) Representative whole-mount immunofluorescent staining of thick femoral sections for CD31 (A and B, green; H and I, red) and EMCN (A and B, red; H, I, blue) of young (8--30 weeks) and old (70--100 weeks) *Nes-gfp* mice with genetically labeled nestin^+^ cells (H and I, green). Arrowheads in insets (A′, B′, H′, and I′) depict CD31^hi^EMCN^−^ capillaries and their coverage by Nes-GFP^+^ cells.(C--G) Quantification of (C) CD31^hi^EMCN^hi^ transition zone vessels, (D) CD31^lo^EMCN^lo^ sinusoids, (E) CD31^hi^EMCN^−^ arterioles with ≥6 μm diameter, and (F) CD31^hi^EMCN^−^ capillaries with \<6 μm diameter. Scale bar, 200 μm (A, B, H, and I), 100 μm (A′, B′, H′, and I′). (G) Frequency of endosteal and non-endosteal BM Nes-GFP^+^ cells from young adult (10--20 weeks, n = 11) and old mice (\>66 weeks, n = 8).(J--N) Concentration of (J) IL-1β, (K) IL-6, (L) IL-1α, (M) IL-3, and (N) IFNγ in endosteal BM extracellular fluid (BMECF) from young WT mice (n = 5) and old WT mice (n = 4). Data are means ± SEM. ^∗^p \< 0.05; ^∗∗^p \< 0.01; ^∗∗∗^p \< 0.001. (C--F and J--N) Unpaired two-tailed t test. (G) One-way ANOVA and Bonferroni pairwise comparisons.

We have previously shown that sympathetic adrenergic signals regulate Nes-GFP^+^ cell proliferation ([@bib37]) and are affected during age-related myeloproliferative neoplasms ([@bib1]). Additionally, increased sympathetic adrenergic activity has been previously described during aging ([@bib23], [@bib43], [@bib59], [@bib64]), chronic stress, and depression ([@bib62]), and might increase osteoporosis and fracture risk by restraining bone formation ([@bib11], [@bib58]). However, the opposite (decreased BM adrenergic innervation) has been recently suggested as causative of HSC aging ([@bib34]). To clarify this, whole-mount preparations of skulls and thick tibial sections of *Nes-gfp* mice were immunostained for tyrosine hydroxylase (TH), to visualize sympathetic noradrenergic fibers and nestin^+^ cells in large 3D volumes. This study did not confirm reduced TH^+^ fibers in the aged BM ([@bib34]) but found these fibers increased by 50% in the skull of old mice ([Figures 2](#fig2){ref-type="fig"}A--2C) and augmented 2.5-fold in the aged tibial BM, compared with the young samples ([Figures 2](#fig2){ref-type="fig"}D--2F). In both cases, nestin^+^ cells were found in proximity of noradrenergic fibers ([Figures S1](#mmc1){ref-type="supplementary-material"}E--S1L). Together, these results suggest contraction of endosteal (bone-associated) HSC niches and expansion of non-endosteal neurovascular HSC niches during aging.Figure 2Increased Sympathetic Nerve Fibers during Aging(A, B, E, and F) Immunofluorescence of tyrosine hydroxylase (TH)^+^ sympathetic noradrenergic nerve fibers (white), CD31^+^ endothelial cells (red), and GFP^+^ cells (green) in the skull (A and B) and tibial (E and F) BM of young (A and E) and old (B and F) *Nes-gfp* mice. Scale bar, 100 μm.(C and D) Area covered by TH^+^ fibers in the (C) skull or (D) tibia of young (n = 12) and old (n = 8) *Nes-gfp* mice. Young mice were analyzed between 8--30 weeks of age, and old mice were 66--120 weeks old. Data are means ± SEM. ^∗^p \< 0.05; ^∗∗^p \< 0.01 (unpaired two-tailed t test).

β-Adrenergic Signals Promote Megakaryopoiesis during Aging {#sec2.2}
----------------------------------------------------------

To study the possible contribution of increased adrenergic innervation to aged hematopoiesis, we analyzed mice lacking β~2~-ΑR and β~3~-ΑR (*Adrb2*^−/−^*Adrb3*^−/−^), the main β-ARs that cooperate in HSC niche regulation ([@bib36]). Importantly, myeloid and megakaryocyte progenitors expanded less in the endosteal BM of aged *Adrb2*^−/−^*Adrb3*^−/−^ mice ([Figures 3](#fig3){ref-type="fig"}A, 3B, and [S2](#mmc1){ref-type="supplementary-material"}A--S2F). Consequently, megakaryocytes did not increase in *Adrb2*^−/−^*Adrb3*^−/−^ mice during aging ([Figures 3](#fig3){ref-type="fig"}C--3G), suggesting a functional role for increased noradrenergic signaling in aged hematopoiesis. Megakaryocytes were less frequently found in apposition to BM sinusoids and could form less protrusions (required for proplatelet formation) in aged *Adrb2*^−/−^*Adrb3*^−/−^ mice ([Figures 3](#fig3){ref-type="fig"}H--3M). Accordingly, aged *Adrb2*^−/−^*Adrb3*^−/−^ mice did not show the increased circulating platelets typically observed in aged WT mice ([Figure 3](#fig3){ref-type="fig"}N), whereas other circulating blood cell types remained unaffected ([Figures S2](#mmc1){ref-type="supplementary-material"}G--S2J). These results suggest that increased β-adrenergic signaling in the BM promotes myeloid differentiation into platelets during aging.Figure 3β-Adrenergic Signals Promote Megakaryopoiesis during Aging(A and B) Representative flow chart (A) and quantification (B) of the frequency of CD41^+^ myeloid or megakaryocyte progenitors within lin^−^sca-1^+^c-kit^+^ (LSK) cells in endosteal BM from young WT mice (n = 7), young *Adrb2*^−/−^*Adrb3*^−/−^ (double knockout \[DKO\]) mice (n = 7), old WT mice (n = 5), and old *Adrb2*^−/−^*Adrb3*^−/−^ mice (n = 4).(C--F) Representative immunofluorescence staining for CD41 (red) and CD42 (green) in femoral BM sections of young (C) or old (D) WT mice and young (E) or old (F) *Adrb2*^−/−^*Adrb3*^−/−^ mice. Arrowheads depict megakaryocytes with protrusions (CD41^+^CD42^+^ cells with cell body extensions). Scale bar, 250 μm.(G and H) Number of CD41^+^CD42^+^ megakaryocytes (G) forming protrusions (H) per BM area (n = 4 young WT; n = 5 young DKO; n = 3 old mice).(I--L) Representative immunofluorescence staining for CD41 (red) and EMCN (green) in femoral BM sections of young (I) or old (J) WT mice and young (K) or old (L) *Adrb2*^−/−^*Adrb3*^−/−^ mice, depicting CD41^+^ megakaryocytes adjacent (arrowheads) or nonadjacent (asterisks) to EMCN^+^ vasculature. Scale bar, 100 μm.(M) Frequency of CD41^+^ cells in contact with EMCN^+^ vasculature (n = 4 young WT; n = 4 young DKO; n = 4 old WT; n = 3 old DKO).(N) Circulating platelets in young (n = 11) and old (n = 6) WT mice, compared with young (n = 9) and old (n = 5) *Adrb2*^−/−^*Adrb3*^−/−^ mice. Young mice were analyzed between 8--30 weeks of age, and old mice were 66--120 weeks old. Data are means ± SEM. ^∗^p \< 0.05; ^∗∗^p \< 0.01; ^∗∗∗^p \< 0.001 (one-way ANOVA followed by Bonferroni pairwise comparisons).

β~2~-AR in the Microenvironment Promotes Megakaryocyte Differentiation {#sec2.3}
----------------------------------------------------------------------

We analyzed single *Adrb2*^−/−^ mice and *Adrb3*^−/−^ mice to understand the role of each β-AR in myelopoietic regulation. Resembling aged *Adrb2*^−/−^*Adrb3*^−/−^ mice ([Figure 3](#fig3){ref-type="fig"}N), aged *Adrb2*^−/−^ mice did not exhibit increased circulating platelets ([Figure 4](#fig4){ref-type="fig"}A), suggesting that increased β~2~-adrenergic activity promotes thrombopoiesis during aging. Already at adulthood, *Adrb2*^−/−^ mice showed reduced frequency of myeloid and megakaryocyte progenitors, and this reduction persisted during aging ([Figures 4](#fig4){ref-type="fig"}B, 4C, [S3](#mmc1){ref-type="supplementary-material"}A, and S3B). We generated BM chimeras using *Adrb2*^−/−^ mice or WT mice as donors/recipients to distinguish hematopoietic cell-autonomous from microenvironmental regulation. WT mice carrying β~2~-AR-deficient hematopoietic cells showed normal frequencies of myeloid and megakaryocyte progenitors ([Figures 4](#fig4){ref-type="fig"}B′--4C′ and [S3](#mmc1){ref-type="supplementary-material"}A′--S3B′). In contrast, *Adrb2*^−/−^ recipients of WT BM cells showed similar reductions as found in primary mice ([Figures 4](#fig4){ref-type="fig"}B″--4C″ and [S3](#mmc1){ref-type="supplementary-material"}A″--S3B″). These results suggest that β~2~-AR signals promote megakaryocyte differentiation through the microenvironment. To obtain mechanistic insight, we treated with selective β~2~-AR or β~3~-AR agonists the HSPC-like HPC-7 cell line ([@bib48]) cultured alone or co-cultured with MS-5 stromal cells, which resemble nestin^+^ BMSCs ([@bib35], [@bib37]; [Figures S3](#mmc1){ref-type="supplementary-material"}C and S3D). Whereas the selective β-AR agonists did not affect megakaryocyte differentiation of HPC-7 cells cultured alone ([Figure S3](#mmc1){ref-type="supplementary-material"}E), β~2~-AR and β~3~-AR agonists had opposite stage-specific effects on megakaryocytic differentiation from HPC-7 cells co-cultured with MS-5 cells. Whereas β~3~-AR agonist increased the frequency of undifferentiated c-kit^hi^CD41^lo^ cells and decreased the fraction of c-kit^lo^CD41^lo^ megakaryocyte progenitors, β~2~-AR agonist did not affect early differentiation, but instead increased the frequency of CD41^hi^ megakaryocytic cells at a later differentiation stage ([Figure S3](#mmc1){ref-type="supplementary-material"}F).Figure 4β~2~-AR Signaling in the Microenvironment Promotes Megakaryocyte Differentiation through IL-6(A) Circulating platelets in young WT (n = 11), young *Adrb2*^−/−^ (n = 3), or old *Adrb2*^−/−^ (n = 3) mice.(B--C″) Frequency of (B, B′, and B″) CD41^+^ myeloid or megakaryocyte progenitors within lin^−^sca-1^+^c-kit^+^ (LSK) cells or (C, C′, and C″) CD150^+^CD41^+^ megakaryocyte progenitors (MkPs) within lin^−^c-kit^+^ (LK) cells in endosteal BM cells of the following mice: (B and C) young WT (B, n = 6; C, n = 3), young *Adrb2*^−/−^ (B, n = 6; C, n = 8) or old *Adrb2*^−/−^ (n = 4) mice; (B′ and C′) lethally irradiated WT recipients of WT (n = 5) or *Adrb2*^−/−^ (n = 4) BM cells; (B″ and C″) lethally irradiated WT (n = 5) or *Adrb2*^−/−^ (n = 4) recipients of WT BM cells.(D) Scheme of human umbilical-cord-blood-derived CD34^+^ HSPCs cocultured with MS-5 stromal cells.(E--G) Representative immunofluorescence (E and F) and number (G) of CD61^+^ (red) human megakaryocytes in cocultures treated with (E) vehicle or (F) β~2~-AR agonist (clenbuterol, 10 μM) for 10 days (n = 3). Scale bar, 250 μm. (F′) Inset of (F).(H) IL6 concentration in endosteal (e) or non-endosteal (n-e) BM supernatant from adult WT (n = 6), *Adrb2*^−/−^ (n = 4), or *Adrb3*^−/−^ (n = 7) mice.(I) *Il6* mRNA expression (fold change) in MS-5 stromal cells treated with β~2~-AR agonist (clenbuterol, 10 μM), PKA inhibitor (H-89, 5 μM), or vehicle for 2 days (n = 3).(J--M) Quantification (J) and representative immunofluorescence (K--M) of CD41^+^ (red) CD42^+^ (green) megakaryocytes (yellow) in adult WT (n = 5), *Adrb2*^−/−^ (n = 3), or *Il6*^−/−^ (n = 5) mice. Scale bar, 250 μm.(N) Myeloid or megakaryocyte progenitors (CD41^+^ LSK cells) in primary BM culture from WT or *Il6*^−/−^ mice treated with β~2~-AR agonist (clenbuterol, 10 μM) or vehicle for 4 days (n = 4). Data are means ± SEM. ^∗^p \< 0.05; ^∗∗^p \< 0.01; ^∗∗∗^p \< 0.001. (B′, B″, C′, C″, and G) Unpaired two-tailed t test. (A, B, C, H, I, J, and N) one-way ANOVA and Bonferroni pairwise comparisons.

To test the potential significance of this regulation in the human setting, we treated human umbilical cord blood-derived hCD34^+^ HSPCs co-cultured with MS-5 cells with a selective β~2~-AR agonist ([Figure 4](#fig4){ref-type="fig"}D). Treatment with β~2~-AR agonist increased the frequency of human CD61^+^ megakaryocytic cells ([Figures 4](#fig4){ref-type="fig"}E--4G). These results suggest that β~2~-AR stimulation of stromal cells promotes megakaryocyte differentiation.

β~2~-AR Indirectly Promotes Megakaryocyte Differentiation through IL-6 {#sec2.4}
----------------------------------------------------------------------

To investigate the underlying mechanism, we measured several cytokines which regulate megakaryopoiesis. Among those, IL-6 concentration increased in WT BM during aging ([Figure 1](#fig1){ref-type="fig"}H) and was low in endosteal *Adrb2*^−/−^ BM ([Figures 4](#fig4){ref-type="fig"}H and [S3](#mmc1){ref-type="supplementary-material"}G--S3I). Moreover, β~2~-AR agonist increased *Il6* mRNA 2-fold in MS-5 stromal cells; this effect was abrogated after blocking protein kinase A ([Figure 4](#fig4){ref-type="fig"}I) downstream of β~2~-AR signaling ([@bib50]). Adult *Adrb2*^−/−^ mice and *Il6*^−/−^ mice showed similarly reduced BM megakaryocytes ([Figures 4](#fig4){ref-type="fig"}J--4M), confirming the role of β~2~-AR and IL6 in megakaryopoiesis. To directly test the role of IL-6 downstream of β~2~-AR, we established primary BM cultures from *Il6*^−/−^ or control mice and treated them with β~2~-AR agonist or vehicle. β~2~-AR agonist tripled myeloid progenitors in WT samples, but not in *Il6*^−/−^ samples ([Figure 4](#fig4){ref-type="fig"}N). Altogether, these results suggest that β~2~-AR on stromal cells promotes megakaryocyte differentiation through IL-6.

β~3~-AR-Deficient Mice Exhibit Altered HSC Lineage Bias {#sec2.5}
-------------------------------------------------------

Our co-culture experiments suggested that, contrasting β~2~-AR, β~3~-AR might inhibit megakaryocytic differentiation ([Figures S3](#mmc1){ref-type="supplementary-material"}C--S3F). Additionally, β~3~-AR stimulation has been shown to promote HSC lymphoid skewing ([@bib34]). Therefore, we measured the frequency of immunophenotypically defined lymphoid-biased HSCs ([Figure S4](#mmc1){ref-type="supplementary-material"}A; [@bib61]). Lymphoid-biased HSCs were reduced by one-third in adult endosteal *Adrb3*^−/−^ BM ([Figures 5](#fig5){ref-type="fig"}A and [S4](#mmc1){ref-type="supplementary-material"}B). This phenotype was not observed in WT mice carrying β~3~-AR-deficient hematopoietic cells ([Figures 5](#fig5){ref-type="fig"}A′ and [S4](#mmc1){ref-type="supplementary-material"}B′) but was reproduced in chimeric mice lacking β~3~-AR in the microenvironment ([Figures 5](#fig5){ref-type="fig"}A″ and [S4](#mmc1){ref-type="supplementary-material"}B″), implying niche-mediated regulation. Opposite trends were observed for long-term HSCs (LT-HSCs) and myeloid-biased HSCs, with their frequencies tending to increase in endosteal *Adrb3*^−/−^ BM ([Figures S4](#mmc1){ref-type="supplementary-material"}C--S4F). These results suggest accelerated lymphoid deficiency in the endosteal microenvironment lacking β~3~-AR.Figure 5Lack of β~3~-AR and Nitric Oxide Synthase 1 (Nos1) Signaling in the Microenvironment Accelerates Aging(A, A′, and A″) Frequency of CD150^lo/−^CD41^−^ lymphoid-biased HSCs in endosteal BM CD34^−^LSK cells from the following mice: (A) young WT (n = 7), young *Adrb3*^−/−^ (n = 7), or old *Adrb3*^−/−^ (n = 5) mice; (A′) lethally irradiated WT recipients of WT (n = 5) or *Adrb3*^−/−^ (n = 5) BM cells; and (A″) lethally irradiated WT (n = 4) or *Adrb3*^−/−^ (n = 3) recipients of WT BM cells.(B) Nitrate concentration in BM extracellular fluid (BMECF) of young WT (n = 6) or *Adrb3*^−/−^ (n = 7) mice.(C) Number of lin^−^sca-1^+^c-kit^+^CD34^−^CD48^−^CD150^+^Vwf-eGFP^−^ lymphoid-biased HSCs in primary BM culture from *Vwf-eGFP* mice treated with β~3~-AR agonist (BRL37344, 10 μM), *Nos1* inhibitor (L-VINO, 100 μM), or vehicle for 4 days (n = 8).(D--G) Representative immunofluorescence (D--F) and quantification (G) of c-kit^+^ (green) CD41^+^ (red) myeloid or megakaryocyte progenitors (arrowheads) in endosteal BM of WT (n = 10), *Adrb3*^−/−^ (n = 8), or *Nos1*^−/−^ (n = 4) mice. Endosteal BM is considered as regions within one-fifth marrow width from the bone surface. Scale bar, 300 μm.(H--K) Representative immunofluorescence (H-J) and quantification (K) of CD41^+^ (red) megakaryocytes adjacent (arrowheads) or nonadjacent (asterisks) to EMCN^+^ (green) BM vasculature of WT (n = 9), *Adrb3*^−/−^ (n = 6), or *Nos1*^−/−^ (n = 4) mice. Scale bar, 250 μm.(L--N′) Representative whole-mount immunofluorescence of CD31 (green) and EMCN (red) in WT (n = 7), *Adrb3*^−/−^ (n = 5), or *Nos1*^−/−^ (n = 4) BM. Arrowheads in insets (L′), (M′), and (N′) depict CD31^hi^EMCN^−^ capillaries.(O and P) Quantification of (O) CD31^hi^EMCN^hi^ transition zone vessels and (P) CD31^hi^EMCN^−^ capillaries with \<6 μm diameter. Scale bar, 250 μm. Data are means ± SEM. ^∗^p \< 0.05; ^∗∗^p \< 0.01; ^∗∗∗^p \< 0.001. (A′ and A″) Unpaired two-tailed t test. (A--C, G, K, O, and P) One-way ANOVA and Bonferroni pairwise comparisons.

We investigated possible mechanisms that might explain the intriguingly opposite effects of β~3~-AR and β~2~-AR signaling on lympho-myeloid lineage skewing. Whereas both β-ARs can activate G proteins ([@bib50]), their differential cardiovascular effects have been attributed to β~3~-AR-dependent nitric oxide (NO) generation ([@bib18]). Therefore, we measured nitrate concentration in the BM extracellular fluid and found it doubled in endosteal (compared with non-endosteal) WT BM and halved in *Adrb3*^−/−^ BM ([Figure 5](#fig5){ref-type="fig"}B). Among NO synthases, *Nos1* (but not *Nos2* or *Nos3*) showed higher mRNA expression in endosteal WT BM and was downregulated in *Adrb3*^−/−^ BM ([Figures S4](#mmc1){ref-type="supplementary-material"}G--S4I). To further study the role of β~3~-AR and Nos1 on HSC lineage bias, we established primary BM cultures from transgenic mice expressing GFP under the regulatory elements of Von Willebrand factor (*Vwf-eGFP*), which discriminate myeloid/platelet-biased (Vwf-eGFP^+^) HSCs from lymphoid-biased (Vwf-eGFP^−^) HSCs ([@bib54]). Treatment with β~3~-AR agonist did not affect platelet-biased HSCs ([Figures S4](#mmc1){ref-type="supplementary-material"}J and S4K) but doubled lymphoid-biased HSCs in a Nos1-dependent manner ([Figure 5](#fig5){ref-type="fig"}C). Moreover, *Adrb3*^−/−^ mice and *Nos1*^−/−^ mice showed similar signs of premature hematopoietic aging; myeloid or megakaryocyte progenitors ([Figures 5](#fig5){ref-type="fig"}D--5G) and megakaryocyte apposition to blood vessels ([Figures 5](#fig5){ref-type="fig"}H--5K) similarly increased in adult *Adrb3*^−/−^ mice and *Nos1*^−/−^ mice. Consistently, transition zone vessels decreased ([Figures 5](#fig5){ref-type="fig"}L--5O) whereas capillaries expanded ([Figure 5](#fig5){ref-type="fig"}P) in both KO models. Despite the partial reduction of lymphoid-biased HSCs in endosteal *Adrb3*^−/−^ BM, the frequencies of circulating lymphocytes or myeloid cells appeared unchanged in 5-month-old *Adrb3*^−/−^ mice ([Figures S4](#mmc1){ref-type="supplementary-material"}L--S4N), contrasting previous findings ([@bib34]). Whereas adult *Adrb3*^−/−^ mice did not yet show in our analysis premature hematopoietic aging in peripheral blood, adult *Nos1*^−/−^ mice showed reduced lymphocytes and increased neutrophils and platelets in circulation ([Figures 6](#fig6){ref-type="fig"}A and 6B), suggesting that other pathways (besides β~3~-AR) contribute to Nos1-dependent regulation of hematopoiesis. Altogether, these results suggest that microenvironmental β~3~-AR contributes to balance HSC lineage-bias toward lymphoid production, which is at least partially dependent on Nos1-dependent NO production.Figure 6Premature Hematopoietic Aging in HGPS Is Not HSC-Autonomous(A--D) Peripheral blood counts in adult (A and B) WT (*Nos1*^*+*/*+*^; n = 15) or *Nos1*^−/−^ (n = 16), and (C and D) WT (*Lmna*^*+*/*+*^; n = 22) or *Lmna*^*G609G*/*G609G*^ (n = 14) mice. (A, C, and K) Frequency of white blood cells (WBC); LYM, lymphocytes; MON, monocytes; NEU, neutrophils. (B, D, and L) Concentration of platelets.(E--G) Frequency of (E) CD11b^+^ myeloid cells, (F) B220^+^ B cells, and (G) CD3^+^ T cells in circulating leukocytes.(H--J) Frequency of (H) CD11b^+^ myeloid cells, (I) B220^+^ B cells, and (J) CD3^+^ T cells among donor-derived leukocytes 120 days after transplantation into WT mice (n = 11).(K and L) Peripheral white blood cell (K) and platelet (L) counts in adult CD45.1 C57BL/6J mice 4 months after lethal irradiation and transplantation with CD45.2 BM cells from WT (n = 8) or *Lmna*^*G609G*/*G609G*^ (n = 6) mice.(M--Q) Concentration of (M) IL-1β, (N) IL-6, (O) IL-1α, (P) IL-3, and (Q) IFNγ in the BM extracellular fluid (BMECF) of adult WT (*Lmna*^*+*/*+*^; n = 9) and *Lmna*^*G609G*/*G609G*^ (n = 9) male mice. Data are means ± SEM. ^∗^p \< 0.05; ^∗∗^p \< 0.01; ^∗∗∗^p \< 0.001 (unpaired two-tailed t test).

Premature Hematopoietic Aging in HGPS Is Not HSC-Autonomous {#sec2.6}
-----------------------------------------------------------

We next interrogated whether the BM microenvironment might promote pathological (and not only physiological) hematopoietic aging. Premature aging in Hutchinson-Gilford progeria syndrome (HGPS) is caused by the accumulation of a truncated prelamin A protein named "progerin," which is produced via aberrant splicing resulting from a *de novo* synonymous c.1824C \> T (p.G608G) point mutation in the *LMNA* gene (encoding lamin A and C) ([@bib8], [@bib13]). This gene has been recently associated with changes in epigenetic and chromatin architecture in aged HSCs ([@bib20]). Progerin also accumulates during normal aging and HGPS displays most aging hallmarks, suggesting that HGPS can inform physiological aging ([@bib33]). *Lmna*^*G609G*^ knockin mice exhibit key hallmarks of the human disease, including accelerated aging, shortened lifespan, and bone and cardiovascular defects ([@bib22], [@bib44], [@bib60]). Certain hallmarks of hematopoietic aging in mice, such as increased circulating platelets, have been observed in HGPS ([@bib38]). However, it remains unknown whether premature aging affects the overall hematopoietic system in HGPS and whether this is a consequence of the *LMNA* mutation in HSCs, other hematopoietic cells and/or their microenvironment.

We measured peripheral blood counts in progeroid mice and control mice. Remarkably, adult progeroid mice resembled adult *Nos1*^−/−^ mice ([Figures 6](#fig6){ref-type="fig"}A and 6B) in their premature myeloid skewing evidenced by decreased lymphocytes and increased neutrophils, monocytes, and platelets ([Figures 6](#fig6){ref-type="fig"}C and 6D), to a similar extent as normally aged mice ([@bib10], [@bib51], [@bib56]). Flow cytometry analysis confirmed increased myeloid cells and decreased lymphoid cells in the peripheral blood of progeroid mice ([Figures 6](#fig6){ref-type="fig"}E--6G).

To test HSC function, lethally irradiated CD45.1 recipients were transplanted with CD45.2 BM cells from *Lmna*^*G609G*/*G609G*^ mice or WT mice, together with competitor BM cells from congenic CD45.1 mice ([Figure S5](#mmc1){ref-type="supplementary-material"}A). Long-term engraftment was lower for *Lmna*^*G609G*/*G609G*^ (compared with WT) hematopoietic cells ([Figure S5](#mmc1){ref-type="supplementary-material"}B), as previously observed for normally aged HSCs ([@bib32]), albeit to a lower extent. However, myeloid skewing was not observed in blood cells derived from *Lmna*^*G609G*/*G609G*^ HSCs ([Figures 6](#fig6){ref-type="fig"}H--6J), suggesting that myeloid skewing is a non-HSC-autonomous aging feature in HGPS. To assess this possibility, we transplanted CD45.2 BM cells from *Lmna*^*G609G*/*G609G*^ mice into lethally irradiated CD45.1 WT recipients. Sixteen weeks later, WT recipients carrying the *Lmna*^*G609G*/*G609G*^ mutation only in hematopoietic cells ([Figures 6](#fig6){ref-type="fig"}K and 6L) did not reproduce the myeloid skewing and increased platelet counts observed in constitutive *Lmna*^*G609G*/*G609G*^ mice ([Figures 6](#fig6){ref-type="fig"}C and 6D). Together, these results suggest that premature aging in HGPS affects the hematopoietic system but cannot be explained by HSC-autonomous alterations. Consistent with this idea, microenvironmental alterations (such as sinusoidal vasodilation) were found in *Lmna*^*G609G*/*G609G*^ BM ([Figures S5](#mmc1){ref-type="supplementary-material"}D and S5E). Moreover, myelopoietic cytokines augmented in normally aged BM microenvironment ([Figures 1](#fig1){ref-type="fig"}J--1N) were also increased in adult progeroid mice ([Figures 6](#fig6){ref-type="fig"}M--6Q).

These results suggested that similar microenvironmental alterations might promote myeloid differentiation during physiological/pathological aging. Therefore, we tested whether targeting the microenvironment could impact hematopoiesis in HGPS. Progeroid mice were chronically treated with a β~3~-AR agonist, which can rescue nestin^+^ niches in humans and mice with age-related myeloproliferative disorders ([@bib1], [@bib9]) and has been recently suggested to rejuvenate normally aged HSCs ([@bib34]). Treatment with β~3~-AR agonist over 2 months normalized circulating granulocytes and lymphocytes and BM neutrophils and partially rescued BM B cells ([Figures 7](#fig7){ref-type="fig"}A--7D). This effect correlated with decreased frequency of BM LT-HSCs ([Figures 7](#fig7){ref-type="fig"}E and 7F).Figure 7β~3~-AR Agonist Improves Lineage Skewing, HSC Number, and Localization near Megakaryocytes in HGPS(A and B) Frequency of (A) granulocytes and (B) lymphocytes in white blood cells (WBCs) of WT mice (n = 8) or *Lmna*^*G609G*/*G609G*^ mice (n = 6) treated with β~3~-AR agonist (BRL37344, 2 mg/kg/day, intraperitoneally \[i.p.\]) or vehicle for 8 weeks.(C--F) Frequency of BM (C) Ly6G^+^CD11b^+^ neutrophils, (D) B220^+^ B cells, endosteal (E), and non-endosteal (F) LT-HSCs in these mice (n = 6).(G--J) Representative immunofluorescence (G--I) and quantification (J) of CD41^+^ megakaryocytes adjacent (asterisks) or nonadjacent (arrowheads) to c-kit^+^ (green) HSPCs in BM of WT mice (n = 3) and *Lmna*^*G609G*/*G609G*^ mice (n = 5) treated with β~3~-AR agonist or vehicle. Scale bar, 50 μm.(K--N) Representative immunofluorescence (K--M) and distribution (N) of BM CD150^+^ (red) HSCs (negative for mature hematopoietic lineage markers, blue) adjacent (asterisks), or nonadjacent (arrows) to CD42^+^ (green) megakaryocytes. Scale bar, 50 μm. Data are means ± SEM. ^∗^p \< 0.05; ^∗∗^p \< 0.01; ^∗∗∗^p \< 0.001. (A--F and J) One-way ANOVA and Bonferroni pairwise comparisons. (N) Two-way ANOVA and Bonferroni pairwise comparisons.

Megakaryocytes have been shown to regulate HSC proliferation ([@bib2], [@bib42], [@bib63]) and their numbers were found to increase during normal/pathological aging in this study. Therefore, we examined the spatial relationships between megakaryocytes and HSPCs in the different models. Like in aged mice ([@bib34]), HSCs expanded but located further from megakaryocytes in adult *Adrb3*^−/−^mice, as an additional premature aging feature in these mice ([Figures S6](#mmc1){ref-type="supplementary-material"}A--S6D). Increased LT-HSC frequency in vehicle-treated progeroid mice (compared with WT mice) ([Figures 7](#fig7){ref-type="fig"}E and 7F) correlated with reduced co-localization of HSPCs and megakaryocytes, which was rescued by β~3~-AR agonist ([Figures 7](#fig7){ref-type="fig"}G--7J). HSCs located more distantly from megakaryocytes in vehicle-treated progeroid mice (compared with WT mice) but this association was partially restored by β~3~-AR agonist ([Figures 7](#fig7){ref-type="fig"}K--7N). These results suggest the possibility that decreased interactions between megakaryocytes and HSCs might reversibly regulate hematopoiesis during aging.

Discussion {#sec3}
==========

This study suggests that alterations of the BM microenvironment during pathological/physiological aging change hematopoiesis. Remodeling of BM HSC niches (namely reduced endosteal niches and increased non-endosteal neurovascular niches) is associated with the overproduction of pro-inflammatory cytokines which drive excessive myelopoiesis in normal/premature aging. However, the latter can be improved by modulating the microenvironment. Together, these results expand previous findings on the microenvironmental contribution to hematopoietic aging to the role of different neurovascular beds in normal and pathological aging, and their potential therapeutic targeting.

Stem cell aging compromises tissue turnover and regeneration, but the contribution of the aged stem cell niche remains incompletely understood ([@bib33]). In the hematopoietic system, HSCs expand during aging but exhibit impaired self-renewal and lymphoid differentiation potential, favoring myeloid output ([@bib32], [@bib40], [@bib45], [@bib51], [@bib53], [@bib56]). Moreover, myeloid malignancies are more frequent in the elderly, but whether changes in the aged HSCs and/or their microenvironment predispose to these malignancies has remained unclear. Although HSC aging was initially regarded as solely derived from intrinsic changes in HSCs ([@bib4], [@bib10], [@bib16], [@bib52]), several alterations in the BM microenvironment or in its interaction with HSCs have been proposed to promote hematopoietic aging ([@bib12], [@bib27], [@bib28], [@bib34]). Our study supports this contention by demonstrating that changes in the microenvironment contribute to physiological hematopoietic aging and pathological premature aging (HGPS). In both settings, the aged microenvironment promotes myeloid differentiation through similar cytokines, such as IL-1β and IL-6.

Progeroid mice exhibit several hallmarks of hematopoietic aging: expanded HSCs with reduced engraftment, lymphoid deficiency, and myeloid skewing toward platelets. However, chimeric mice carrying *Lmna*^*G609G*/*G609G*^ hematopoietic cells in a WT environment do not reproduce the hematopoietic aging of progeroid mice. Together with the altered vasculature and increased concentration of myelopoietic cytokines in progeroid BM, these results strongly suggest that the BM microenvironment causes premature hematopoietic aging in HGPS. In fact, chronic treatment of progeroid mice with β~3~-AR agonist (targeting the microenvironment) reduces HSCs and restores their proximity to megakaryocytes and their lympho-myeloid skewing.

During physiological aging, endosteal BM niches decrease, consistent with previous observations ([@bib30]), whereas non-endosteal neurovascular BM niches containing Nes-GFP^+^ stromal cells show a pronounced expansion. This microenvironmental remodeling might directly favor myeloid expansion during aging, because lymphoid niches have been found near bone ([@bib41]), whereas myeloid cell expansion and thrombopoiesis mainly occurs in non-endosteal niches ([@bib14]).

Recently, an age-related reduction of BM adrenergic nerve fibers has been reported to dive most hallmarks of HSC aging ([@bib34]). However, studies on BM innervation during aging have provided conflicting results, with BM adrenergic fibers reportedly been dramatically reduced ([@bib34]), unchanged, or increased ([@bib5]). The whole-mount or thick section imaging and 3D reconstruction of different bones in the present study supports the latter and demonstrates that these fibers are doubled in different bones during physiological aging. Moreover, these fibers are not reduced in adult progeroid mice ([Figure S7](#mmc1){ref-type="supplementary-material"}), which exhibit premature hematopoietic aging. Our findings are consistent with the well-known increase in sympathetic activity in the elderly ([@bib23], [@bib43], [@bib59], [@bib64]) and suggest a functional change of neurotransmission (β~2~-AR overriding β~3~-AR), rather than a general decline of BM innervation during aging. Actually, increased noradrenergic activity in the BM seems to account for augmented thrombopoiesis in aged mice because platelets are not elevated in aged *Adrb2*^−/−^ mice or *Adrb2*^−/−^*Adrb3*^−/−^ mice. A previous study showed direct effects of α-ARs on mature megakaryocyte adhesion, proplatelet formation, and platelet release, whereas α-AR signaling on more primitive CD34^+^ progenitor cells did not affect lineage commitment ([@bib6]). However, the present study indicates that HSPC lineage commitment is regulated by the microenvironment through β~2~-AR and β~3~-AR. Therefore, BM noradrenergic activity appears to regulate lineage commitment and megakaryopoiesis at different stages of maturation through distinct α- and β-ARs. Interestingly, β~2~-AR and β~3~-AR exhibit opposite roles on myeloid differentiation: whereas β~2~-AR signaling promotes megakaryopoiesis through stromal-cell-derived IL6 and becomes predominant during aging, β~3~-AR inhibits myelopoiesis. Lack of β~2~-AR in the microenvironment (but not in the hematopoietic system) halves myeloid and megakaryocyte progenitors in adult mice. Decreased frequency of megakaryocyte lineage cells is similarly found in adult *Adrb2*^−/−^ mice and aged *Adrb2*^−/−^*Adrb3*^−/−^ mice (but not in WT chimeras carrying *Adrb2*^−/−^ hematopoietic cells), suggesting that predominant β~2~-AR activation promotes megakaryocyte differentiation during aging. Whereas adult *Adrb2*^−/−^ mice and *Adrb3*^−/−^ mice exhibit opposite deregulation of lymphoid/myeloid lineage output, only *Adrb2*^−/−^ mice retain this phenotype upon aging ([Figures 4](#fig4){ref-type="fig"}B, 4C, and [5](#fig5){ref-type="fig"}A), further suggesting that β~2~-AR prevails over β~3~-AR in hematopoietic lineage regulation during aging. This regulation requires IL-6, a cytokine known to increase in elderly humans ([@bib3]) and to be similarly regulated in other cell types ([@bib31]). Supporting the role of IL6, megakaryocytes appear decreased in *Il6*^−/−^ BM. Moreover, β~2~-AR agonist specifically increased IL-6 expression in stromal cells co-cultured with human/murine HSPCs and consequently stimulates megakaryopoiesis in these co-cultures or in primary BM cultures from WT mice, but not *Il6*^−/−^ mice.

In contrast, microenvironmental (but not hematopoietic) lack of β~3~-AR partially reduces lymphoid-biased HSCs in adult mice, as previously reported ([@bib34]). However, the results here differ in that β~3~-AR loss does not appear overall sufficient to cause premature hematopoietic aging, because the frequencies of circulating lymphocytes and myeloid cells appeared unchanged in 5-month-old *Adrb3*^−/−^ mice. *In vitro*, β~3~-AR agonist-treated stromal cells decrease human and murine HSPC differentiation into megakaryocytes. This effect requires Nos1, because *Nos1*^−/−^ mice have high circulating platelets and granulocytes, but low circulating lymphocytes. Furthermore, β~3~-AR agonist specifically increases lymphoid-biased HSCs in primary BM cultures in a Nos1-dependent manner. Moreover, adult *Adrb3*^−/−^ or *Nos1*^−/−^ mice share premature microenvironmental aging features in the BM, such as reduced bone-forming transition zone vessels ([@bib30]) and increased BM capillaries, myeloid progenitors, and megakaryocyte apposition to blood vessels.

Megakaryocytes inhibit HSC proliferation ([@bib2], [@bib42], [@bib63]). Whereas both HSCs and megakaryocytes expand during aging, HSCs locate further from megakaryocytes in adult *Adrb3*^−/−^ mice and progeroid mice, suggesting that decreased HSC-megakaryocyte interactions might contribute to premature hematopoietic aging features in these mice. Supporting this possibility, chronic treatment of progeroid mice with β~3~-AR agonist decreased HSCs and corrected lineage skewing, correlated with normalized distribution of HSCs near megakaryocytes. Future studies will be required to investigate changes in the regulation of HSC proliferation by megakaryocytes during aging.

In summary, this study shows that the aged BM microenvironment promotes myeloid expansion during physiological aging and in premature aging. Normal murine aging concurs with the reduction of endosteal niches and the expansion of non-endosteal niches comprising capillaries and nestin^+^ cells associated with sympathetic noradrenergic fibers. Interestingly, β~2~-AR and β~3~-AR regulate myelopoiesis through opposite and stage-dependent effects on the hematopoietic microenvironment. During normal aging, increased β~2~-AR activity promotes IL6-dependent myeloid differentiation, whereas decreased β~3~-AR-Nos1-NO is associated with reduced endosteal niches and increased central niches. Adult Nos1 KO mice and progeroid mice display premature aging in peripheral blood, manifested as reduced lymphocytes and increased myeloid cells. Megakaryocytes move closer to BM sinusoids in *Adrb3*^−/−^ or progeroid mice, possibly explaining increased thrombopoiesis. Megakaryocytes and HSCs expand but separate from each other during normal aging and in adult *Adrb3*^−/−^ or progeroid mice. However, chronic treatment of progeroid mice with β~3~-AR agonist reduces HSCs and restores their proximity to megakaryocytes and their lympho-myeloid skewing. Therefore, normal or premature niche aging promotes normal myeloid expansion, which can be improved by targeting the microenvironment.
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REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**CD45.1 (A20)BD BiosciencesCat\#560578; RRID:[AB_1727488](nif-antibody:AB_1727488){#interref20}CD45.2 (104)TONBO BiosciencesCat\#20-0454-U100; RRID:[AB_2621576](nif-antibody:AB_2621576){#interref195}B220 (RA3-6B2)BD BiosciencesCat\#553088; RRID:[AB_394618](nif-antibody:AB_394618){#interref25}CD11b (M1/70)BioLegendCat\#101208; RRID:[AB_312791](nif-antibody:AB_312791){#interref30}CD3ε (145-2C11)TONBO BiosciencesCat\#65-0031-U100; RRID:[AB_2621872](nif-antibody:AB_2621872){#interref35}Ly-6G (RB6-(C5)BioLegendCat\#127623; RRID:[AB_10645331](nif-antibody:AB_10645331){#interref40}CD90 (53-2.1)BD BiosciencesCat\#553003; RRID:[AB_394542](nif-antibody:AB_394542){#interref45}sca-1 (E13-161.7)BioLegendCat\#108128; RRID:[AB_2563064](nif-antibody:AB_2563064){#interref50}CD42d (1C2)Fisher Scientific LtdCat\#17-0421-80; RRID:[AB_1724073](nif-antibody:AB_1724073){#interref55}biotinylated lineage antibodies (CD11b, Gr-1, Ter119, B220, CD3ε)BD BiosciencesCat\#559971; RRID:[AB_10053179](nif-antibody:AB_10053179){#interref60}c-kit (2B8)Thermo Fisher ScientificCat\#11-1171-81; RRID:[AB_465185](nif-antibody:AB_465185){#interref65}CD150 (TC15-12F12.2)BioLegendCat\#115927; RRID:[AB_11204248](nif-antibody:AB_11204248){#interref70}CD34 (RAM34)BD BiosciencesCat\#560238; RRID:[AB_1645242](nif-antibody:AB_1645242){#interref75}CD41 (MWReg30)BioLegendCat\#133905; RRID:[AB_2265179](nif-antibody:AB_2265179){#interref80}Brilliant Violet 510 StreptavidinBioLegendCat\#405233anti-CD45-biotinylated antibodyBD BiosciencesCat\#553078; RRID:[AB_394608](nif-antibody:AB_394608){#interref85}anti-Ter119 --biotinylated antibodyBD BiosciencesCat\#553672; RRID:[AB_394985](nif-antibody:AB_394985){#interref90}anti-CD31-APC antibodyBD BiosciencesCat\#551262; RRID:[AB_398497](nif-antibody:AB_398497){#interref95}Streptavidin-APCCy7BD BiosciencesCat\#554063; RRID:[AB_10054651](nif-antibody:AB_10054651){#interref100}anti-ckit-FITC antibodyBD PharMingenCat\#553354; RRID:[AB_394805](nif-antibody:AB_394805){#interref105}anti-CD41-PE antibodyBD PharMingenCat\#558040; RRID:[AB_397004](nif-antibody:AB_397004){#interref110}Human/Mouse CD117/c-kit Antibody (Polyclonal Goat IgG)R&DCat\#AF1356; RRID:[AB_354750](nif-antibody:AB_354750){#interref115}rat anti-CD150 antibodyBiolegendCat\#115902; RRID:[AB_313681](nif-antibody:AB_313681){#interref120}CD34 Microbead kitMiltenyi BiotecCat\#130-046-702rabbit anti-TH antibodyMilliporeCat\#AB152; RRID:[AB_390204](nif-antibody:AB_390204){#interref125}Alexa Fluor 647 goat anti-rat IgGLife TechnologiesCat\#A21247; RRID:[AB_141778](nif-antibody:AB_141778){#interref130}anti-rabbit biotinylated antibodyJackson ImmunoResearch LabsCat\#111-066-003; RRID:[AB_2337966](nif-antibody:AB_2337966){#interref135}Cy3-Tyramide secondary antibodyPerkin ElmerCat\#SAT704A001EArat anti-EMCN antibodySanta Cruz BiotechnologyCat\#sc-65495; RRID:[AB_2100037](nif-antibody:AB_2100037){#interref140}goat anti-CD31 antibodyR&DCat\#AF3628; RRID:[AB_2161028](nif-antibody:AB_2161028){#interref145}Alexa Fluor 546 Donkey anti-rabbit IgGThermo Fisher ScientificCat\#A10040; RRID:[AB_2534016](nif-antibody:AB_2534016){#interref150}Dylight650 donkey anti-rat IgGThermo Fisher ScientificCat\#SA5-10029; RRID:[AB_2556609](nif-antibody:AB_2556609){#interref155}Cy3-donkey anti-goat IgGJackson ImmunoResearch LabsCat\#705-165-147; RRID:[AB_2307351](nif-antibody:AB_2307351){#interref160}Alexa Fluor 647 donkey-anti-goat IgGLife TechnologiesCat\#A21447; RRID:[AB_141844](nif-antibody:AB_141844){#interref165}Alexa Fluor 647 Goat-anti-armenian hamster IgGAbcamCat\#ab173004; RRID:[AB_2732023](nif-antibody:AB_2732023){#interref170}mouse-anti-human CD61 primary antibodySerotecCat\#MCA728; RRID:[AB_321515](nif-antibody:AB_321515){#interref175}Alexa Fluor 546 donkey-anti-mouse IgGThermo Fisher ScientificCat\#A10036; RRID:[AB_2534012](nif-antibody:AB_2534012){#interref180}Alexa Fluor 488 Sreptavidin-conjugated antibodyThermo Fisher ScientificCat\#S32354; RRID:[AB_2315383](nif-antibody:AB_2315383){#interref185}Alexa Fluor 555 goat-anti-rat IgGThermo Fisher ScientificCat\#A21434; RRID:[AB_2535855](nif-antibody:AB_2535855){#interref190}**Chemicals, Peptides, and Recombinant Proteins**Trizol ReagentSigma-AldrichCat\#T9424α-MEM mediumStemCell TechnologiesCat\#36450MyeloCult M5300 mediumStemCell TechnologiesCat\#05350StemSpan H3000 mediumStemCell TechnologiesCat\#09850IMDM mediumThermoFisherCat\#12440053Ammonium chlorideSigma-AldrichCat\#254134collagenase type IStem Cell TechnologiesCat\#07902DAPISigma AldrichCat\#D9542mSCFPeProTechCat\#250-03-100TPOPeProTechCat\#AF-300-18EPOR&DCat\#287-TC-500IL-1βCellgenixCat\#1411-050BRL37344Sigma-AldrichCat\#B169H-89Sigma-AldrichCat\#B1427Clenbuterol hydrochlorideSigma-AldrichCat\#C5423hydrocortisoneStemCell TechnologiesCat\#07904Avidin/biotin blocking kitVector LaboratoriesCat\#SP-2001Triton X-100Sigma-AldrichCat\#T8787TNB (0.1 M Tris--HCl, pH7.5, 0.15 M NaCl, 0.5% blocking reagent)Perkin ElmerCat\#FP1020DPX Mountant for histologySigma-AldrichCat\#44581donkey serumSigma-AldrichCat\#D9663rat serumSigma-AldrichCat\#R9759Dako Fluorescence Mounting MediumAgilentCat\#S3023DMSOSigma-AldrichCat\#D5879**Critical Commercial Assays**Lympholyte®-M Cell Separation MediaCedarlaneCat\#CL5031ABC amplification kitVector LabsCat\#AK-5000MILLIPLEX MAP Mouse Cytokine/Chemokine Magnetic Bead PanelMerck MilliporeCat\#MCYTOMAG-70KHigh-Capacity cDNA Reverse Transcription kitApplied BiosystemsCat\#4368814PowerUp SYBR Green Master MixApplied BiosystemsCat\#A25742**Experimental Models: Organisms/Strains***Nes-gfp*Prof. Grigori N. Eikolopov, Stony Brook, USA[@bib39]*Adrb2*^*−/−*^Prof. Gerard Karsenty, Columbia University, New York, USA[@bib7]*FVB/N-Adrb3tm1Lowl/J*The Jackson LaboratoryStock\#6402, backcrossed to C57BL/6J for 10 generations*Lmnatm1.1Otin*Prof. Carlos López-Otín, Oviedo University, Spain[@bib44]*Vwf-eGFP*Prof. Claus Nerlov, University of Oxford, UK[@bib54]*Nos1tm1Plh/J*The Jackson LaboratoryStock\#2986*Il6tm1Kopf/J*The Jackson LaboratoryStock\#2650congenic CD45.1 C57BL/6Charles River LaboratoriesN/Acongenic CD45.2 C57BL/6Charles River LaboratoriesN/A**Experimental Models: Cell lines**MS-5DSMZACC 441HPC-7Prof. Leif Carlsson, Umeå University, SwedenN/A**Oligonucleotides**NOS1-Fw: ACTGACACCCTGCACCT\
GAAGASigma-AldrichN/ANOS1-Rv: GTGCGGACATCTTCTGA\
CTTCCSigma-AldrichN/ANOS2-Fw: CAGCTGGGCTGTACAAACCTTSigma-AldrichN/ANOS2-Rv: CATTGGAAGTGAAGCGGTTCGSigma-AldrichN/ANOS3-Fw: CCTCGAGTAAAGAACTGG\
GAAGTGSigma-AldrichN/ANOS3-Rv: AACTTCCTTGGAAACAC\
CAGGGSigma-AldrichN/AGapdh-Fw: GCATGGCCTTCCGTGTTCSigma-AldrichN/AGapdh-Rv: CTGCTTCACCACCTTCTTGATSigma-AldrichN/A
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Further information and requests for resources and reagents should be addressed to the Lead Contact, Dr. Simon Mendez-Ferrer, at <sm2116@medschl.cam.ac.uk>.

Methods Details {#sec4.3}
---------------

### Mouse strains {#sec4.3.1}

Young mice were analyzed between 8-30 weeks of age, and old mice were 66-120 weeks old. Mice were housed in specific pathogen free facilities. All experiments using mice followed protocols approved by the Animal Welfare Ethical Committees, according to EU and United Kingdom Home Office regulations (PPL 70/8406). *Nes-gfp* ([@bib39]), *Adrb2*^*−/−*^ ([@bib7]), *FVB/N-Adrb3tm1Lowl/J* ([@bib57]), *Lmnatm1.1Otin* ([@bib44]), *Vwf-egfp* ([@bib54]), *B6.129S4-Nos1tm1Plh/J* (stock\#2986) ([@bib25]), *B6.129S2-Il6tm1Kopf/J* (stock\#2650) ([@bib29]) (Jackson Laboratories) and congenic CD45.1 and CD45.2 C57BL/6 mice (Charles River Laboratories) were used in this study.

### Mouse bone marrow transplantation and *in vivo* treatments {#sec4.3.2}

In *Lmna*^*G609G/G609G*^ mouse model, HSC activity was assessed by long-term competitive repopulation assay using the congenic CD45.1/CD45.2 isotypes. Recipient female CD45.1 C57BL/6 mice (8 week-old) were subjected to lethal irradiation (12 Gy whole body irradiation, split dose 6.0 + 6.0 Gy, 3 h apart). 10^6^ BM nucleated cells from (CD45.2) WT mice or LmnaG619G/G609G mice were mixed with 10^6^ BM nucleated cells from CD45.1 C57BL/6 mice and i.v. transplanted in 200 μL sterile PBS into lethally irradiated CD45.1 C57BL/6 mice. At various time points after transplantation (4, 8, 12 and 16 weeks), peripheral blood nucleated cells were collected from recipients. Cells were stained with fluorescent-conjugated antibodies against B220, Mac1 and CD90 antigens, and analyzed by fluorescence-activated cell sorting. The selective β3-AR agonist BRL37344 (Sigma, St. Louis, MO) was administered at 2mg/kg through intraperitoneal (i.p.) injection once per day. Vehicle (saline solution) daily injections were performed in the same way. Treatment was initiated when *Lmna*^*G609G/G609G*^ mice were 7 weeks old and lasted for 8 weeks.

To generate chimeric mice carrying *Adrb2*^*−/−*^ or *Adrb3*^*−/−*^ BM cells, two-month-old C57BL/6 mice were lethally irradiated (12 Gy, two split doses) and i.v. transplanted with 2 X 10^6^ nucleated BM cells from two-month-old WT, *Adrb2*^*−/−*^ or *Adrb3*^*−/−*^ mice. To test microenvironment-dependent effects of β-adrenergic signaling, WT, *Adrb2*^*−/−*^ or *Adrb3*^*−/−*^ (CD45.2) mice were lethally irradiated (12 Gy, two split doses) and i.v. transplanted with 2 X 10^6^ nucleated BM cells from CD45.1 C57BL/6 mice. Hematopoietic cells in the BM were analyzed 4 months after transplantation in both settings.

### BM cell extraction, flow cytometry and fluorescence-activated cell sorting {#sec4.3.3}

For BM hematopoietic cell isolation, bones were crushed in a mortar, filtered through a 40-μm strainer to obtain single cell suspensions, and depleted of red blood cells by lysis in 0.15 M NH~4~Cl for 10 min at 4°C. Blood samples were directly lysed. Cells were incubated with the appropriate dilution (2-5 μg/ml) of fluorescent antibody conjugates and 4',6-diamidino-2-phenylindole (DAPI) for dead cell exclusion, and analyzed on LSRFortessa flow cytometer (BD Biosciences, Franklin Lakes, NJ) equipped with FACSDiva Software (BD Biosciences). The following antibodies were used: fluorescent CD45.1 (A20), CD45.2 (104), B220 (RA3-6B2), CD11b (M1/70), CD3ε (145-2C11), Ly-6G (1A8), CD90 (53-2.1) sca-1 (E13-161.7), CD42d (1C2), biotinylated lineage antibodies (CD11b, Gr-1, Ter119, B220, CD3ε) (BD Biosciences), c-kit (2B8) (eBioscience), CD150 (TC15-12F12.2), CD34 (RAM34) and CD41 (MWReg30) (BioLegend). Biotinylated antibodies were detected with fluorochrome conjugated streptavidin (BD Biosciences).

To isolate endosteal and non-endosteal HSPCs, long bones were flushed gently to obtain hematopoietic cells less tightly associated with the bone and then flushed-bones were crushed in a mortar to obtain hematopoietic cells enriched in the endosteal compartment. Cells were stained with the above-mentioned antibodies and analyzed by flow cytometry or sorted (FACS Aria cell sorter, BD Bioscience). Long-term HSCs (LT-HSCs) were immunophenotypically defined as lin-sca-1+ckit+CD34-CD150+CD41- cells. Myeloid-biased HSCs were immunophenotypically defined as lin-sca-1+ckit+CD34-CD150+CD41+ cells. Lymphoid-biased HSCs were immunophenotypically defined as lin-sca-1+ ckit+CD34-CD150-CD41- cells.

For analysis of Nes-GFP+ cell distribution in endosteal and non-endosteal BM fractions, the long bones were flushed with PBS and remaining endosteal part was crushed in a mortar. Both fractions were digested in 2ml of collagenase type I (Stem Cell Technologies, cat. No. 07902) for 30 min at 37°C with agitation. The enzyme was quenched by adding 18ml PBS/2%FCS. Cell suspensions were filtered, pelleted and red blood cell lysis was performed as stated above. Samples were stained with the following antibodies: 1:100 anti-CD45-biotinylated ab (BD Biosciences, cat. No. 553078), 1:100 anti-Ter119 --biotinylated ab (BD Biosciences, cat. No. 553672), 1:100 anti-CD31-APC ab (BD Biosciences, cat. No. 551262). Subsequently, cells were stained with Streptavidin-APCCy7 1:200 (BD Biosciences, cat. No. 554063). DAPI (Sigma Aldrich, cat.no. D9542) was added at 1:10 000 to discriminate dead cells. Samples were acquired on Gallios flow cytometer (Beckman Coulter) and a LSRFortessa cell analyzer (BD Biosciences) and were analyzed with Kaluza analysis software (Beckman Coulter).

### Cell culture {#sec4.3.4}

HPC-7 cells were maintained in IMDM medium supplemented with 10% FCS and 100 ng/ml of mSCF (PeProTech 250-03).

MS-5 cells were maintained in α-MEM medium supplemented with 10% FCS. To induce megakaryocyte differentiation, HPC-7 cells were cultured with or without MS-5 stromal cells in StemSpan H3000 medium, supplemented with 50 ng/ml of TPO (PeProTech 300-18) and 2U/mL of EPO (R&D 287-TC-500) up to 4 days. 10 μM of BRL37344 (β3-AR agonist; Sigma B169), 10 μM of clenbuterol (β2-AR agonist; Sigma C5423), 5 μM of H-89 (Protein kinase A inhibitor; Sigma B1427) and vehicle controls were added to the culture. To examine megakaryocyte differentiation, cells were incubated with anti-ckit-FITC ab (1:200, BD PharMingen 553354) and anti-CD41-PE ab (1:200, BD PharMingen 558040). DAPI was added at 1:10,000 to discriminate dead cells. Samples were analyzed by Gallios flow cytometer (Beckman Coulter).

Human umbilical cord blood CD34+ HSPCs were isolated using a CD34 Microbead kit (Miltenyi Biotec 130-046-702) following manufacturer's instructions, and were cultured with MS-5 stromal cells in Cellgro medium (CellGenix cat. no. 20802-0500), supplemented with 50 ng/ml of TPO (PeProTech 300-18) and 5 ng/ml of IL-1β (Cellgenix 1411-050) for 7-10 days, during which vehicle, 10 μM of BRL37344 (β3-AR agonist; Sigma B169) or 10 μM of clenbuterol (β2-AR agonist; Sigma C5423) were added to the culture. Conditioned medium was refreshed at day3 and day7 of the coculture. To examine megakaryocyte differentiation, cells were fixed and stained with anti-human CD61 antibody (Serotec MCA 728).

For mouse bone marrow long-term culture, femurs and tibias were flushed gently to obtain bone marrow cells. Cells were seeded and cultured in MyeloCult M5300 medium (StemCell Technologies, cat. no. 05350) supplemented with 10^−6^ M hydrocortisone (StemCell Technologies, cat. no. 07904) at 33°C for 14 days. Half of the medium was refreshed at day 7. At day 14 of culture, half of the medium was refreshed again and added with 50 ng/ml of TPO (PeProTech 300-18) for 4 days, during which vehicle, 10 μM of BRL37344 (β3-AR agonist; Sigma B169), 10 μM of clenbuterol (β2-AR agonist; Sigma C5423), or 100 μM of L-VINO (Insight Biotechnology 728944-69-2) were added to the culture. At day 18 of culture, cells were collected and subjected to flow cytometry analysis.

### Immunofluorescence staining {#sec4.3.5}

Immunofluorescence staining of cryostat sections was performed as previously described ([@bib26]), with minor modifications. Briefly, tissues were permeabilized with 0.1% Triton X-100 (Sigma) for 10 min at RT and blocked with TNB buffer (0.1 M Tris--HCl, pH 7.5, 0.15 M NaCl, 0.5% blocking reagent, Perkin Elmer) for 1 h at RT. Primary antibody incubations were conducted for 2 h at RT. Secondary antibody incubations were conducted for 1 h at RT. Repetitive washes were performed with PBS + 0.05% Triton X-100. Stained tissue sections were counterstained for 5 min with 5 μM DAPI and rinsed with PBS. Slides were mounted in Vectashield Hardset mounting medium (Vector Labs) and sealed with nail polish. Skull bones were fixed with 2% PFA for 2h in 4C, washed with PBS and cut through the sagittal suture. Each half was permeabilized with PBS-0.1% Triton with 20% goat serum (Thermo Scientific, cat. No. 9722) overnight at 4°C on the rocker. Endogenous biotin was blocked with the Avidin/biotin blocking kit (Vector Laboratories, cat. No. SP-2001) according to manufacturer's recommendation. Endogenous peroxidase was blocked with 0.4% peroxide (Sigma-Aldrich, cat. no. H1009) for 2h at RT. Subsequently, the skull bones were stained with rat anti-CD31 (BD Biosciences, cat. no. 551262) and rabbit anti-TH (Millipore, cat. no. AB152) in 0.1% Triton-20%goat serum-PBS (diluted 1:100 and 1:500 respectively) for 3 days, and washed over the next day with 0.05% Triton - PBS- at RT on a rocker. Samples were stained with secondary goat anti-rat-Alexa647 at 1:300 (Life Technologies, cat. no. A21247) and goat anti-rabbit biotinylated at 1:200 (Stratech Scientific, cat. no. 111-066-003) o/n at 4°C. Subsequently, the skull bones were treated with ABC amplification kit (Vector Labs) to detect Cy3-Tyrmide amplified signal from TH staining (Perkin Elmer, cat.no. SAT704A001EA). As a final step, the skull bones were stained with DAPI 1:1000 for 5 min. Images were acquired with Leica TCS SP5 confocal microscope with 10x objective. From each sample, 3 representative images were collected in different areas: frontal bone near bregma, central sinus of parietal bone and interparietal bone near lambda. The TH+ area was analyzed with ImageJ. For whole mount staining of long bones, tibia or femur BM thick sections were obtained with a cryostat and remaining OCT was removed by PBS washes. Samples were blocked and permeabilized in 0.1% Triton X-100 (Sigma) TNB (0.1 M Tris--HCl, pH7.5, 0.15 M NaCl, 0.5% blocking reagent, Perkin Elmer) overnight at 4°C. On the next day, samples were incubated with rabbit anti-TH (Merck AB152; 1:200), goat anti-CD31 (R&D AF3628 1:100), rat anti-EMCN (Insight Biotechnology sc-65495 1:100) or rat anti-CD31 (BD Biosciences Clone MEC13.3; 1:200) diluted in 0.1% Triton X-100 TNB overnight at 4°C. Samples were rinsed with 0.05% Triton X-100 PBS for 8 hours and incubated overnight with secondary antibodies including A546 Donkey anti-rabbit IgG (Invitrogen A10040; 1:200), Dylight650 donkey anti-rat IgG (Thermo Fisher SA5-10029; 1:300), Cy3-donkey anti-goat IgG (Jackson 705-165-147, 1:300) diluted in TNB. Samples were rinsed with 0.05% Triton X-100 PBS for 4 hours, washed with PBS and counterstained with DAPI (Sigma; 1:1000) to label cell nuclei. Images were acquired with Leica SP5 confocal microscope using 10x, 20x and 40x objectives and analyzed with ImageJ. At least 3 independent and randomly selected BM areas were imaged and analyzed per sample. To quantify neural fibers, total TH+area was normalized per total BM area labeled with DAPI. For quantification of sinusoidal vessel area, EMCN+ area \> 150 μm distant to the bone surface was measured and normalized to BM area. Arteriolar (\> 6 μm diameter) and capillary (\< 6 μm diameter) CD31hiEMCN- vessel number was counted and normalized to BM area. To quantify transition zone vessels, CD31hiEMCNhi area \< 150 μm close to the bone surface was quantified and normalized to the bone surface length.

For staining of megakaryocyte and megakaryocyte progenitor ([Figures 3](#fig3){ref-type="fig"}C--3F, [4](#fig4){ref-type="fig"}J--4L, [5](#fig5){ref-type="fig"}D--5F, [7](#fig7){ref-type="fig"}G--7I, and [S2](#mmc1){ref-type="supplementary-material"}A--S2D), BM femur thin sections were blocked with TNB for 1h at RT. Samples were then incubated with primary antibodies for 2 h at RT or overnight at 4°C, followed by secondary antibodies incubation for 1h at RT. Finally, samples were counterstained with DAPI to label cell nuclei. Repetitive washes were performed with PBS. At least 3 independent and randomly selected BM areas were imaged and analyzed by ImageJ. The following primary antibodies were used: CD41 (1:200, PE conjugated rat monoclonal antibody, BD PharMingen 558040), CD42d (1:100, APC conjugated armenian hamster monoclonal antibody, eBioscience 17-0421-80) and ckit (1:100, goat polyclonal antibody, R&D AF1356). The following secondary antibodies were used: Alexa Fluor 647 Goat-anti-armenian hamster IgG (1:200, Abcam ab173004) and Alexa Fluor 647 donkey-anti-goat IgG (1:200, Life Technologies A21447).

For staining of megakaryocyte localization relative to sinusoids ([Figures 3](#fig3){ref-type="fig"}I--3L and [5](#fig5){ref-type="fig"}H--5J), BM femur thin sections were blocked with 0.1% Triton X-100 TNB for 1h at RT. Samples were then incubated with rat anti-EMCN (Insight Biotechnology sc-65495 1:100) antibody diluted in 0.1% Triton X-100 TNB overnight at 4°C. On the next day, samples were incubated with Alexa Fluor 647 goat-anti-rat IgG (1:200, Life Technologies, cat. no. A21247) secondary antibody for 1h at RT, followed by rat serum blocking (1:10 rat serum in 0.05% Triton X-100 TNB) for 10 min. Samples were incubated with third antibody, CD41 (1:200, PE conjugated rat monoclonal antibody, BD PharMingen 558040) for 2h at RT. Finally, samples were counterstained with DAPI to label cell nuclei. Repetitive washes were performed with PBS or 0.05% Triton X-100 PBS. At least 3 independent and randomly selected BM areas were imaged and analyzed by ImageJ.

For HSCs and megakaryocytes staining ([Figures 7](#fig7){ref-type="fig"}, [S5](#mmc1){ref-type="supplementary-material"}, and [S6](#mmc1){ref-type="supplementary-material"}), BM femur thin sections were blocked with TNB for 1h at RT and followed by Avidin/biotin blocking. Samples were then incubated with rat anti-CD150 (1:50, Biolegend Cat. No. 115902) and armenian hamster anti-CD42d (1:100, eBioscience 17-0421-80) primary antibodies overnight at 4°C. On the next day, samples were incubated with Alexa Fluor 555 goat-anti-rat IgG (1:200, Life Technologies A21434) and Alexa Fluor 647 Goat-anti-armenian hamster IgG (1:200, Abcam ab173004) secondary antibodies for 1h at RT, followed by rat serum blocking (1:10 rat serum in TNB) for 10 min. Samples were re-stained with biotinylated lineage antibodies (1:100, BD Biosciences) for 2h at RT. Finally, samples were incubated with Alexa Fluor 488 Streptavidin-conjugated antibody (1:200, Invitrogen S32354) for 1h at RT and counterstained with DAPI to label cell nuclei. At least 3 independent and randomly selected BM areas were imaged and analyzed by ImageJ.

For staining of human cord blood CD34+ HSPC co-culture ([Figures 4](#fig4){ref-type="fig"}D and 4E), cells were fixed with 1% PFA for 20 mins at RT. After PBS washes, cells were blocked with 10% donkey serum (Sigma D9663) diluted in PBS for 1h at RT, followed by 2h incubation of mouse-anti-human CD61 primary antibody (1:500, Serotec MCA 728). After PBS washes, cells were incubated with Alexa Fluor 546 donkey-anti-mouse IgG (1:200, Life Technologies, cat. no. A10036) secondary antibody for 1h at RT. Finally, samples were counterstained with DAPI to label cell nuclei. 10 independent and randomly selected fields in culture wells were imaged and analyzed by ImageJ.

### RNA isolation and qPCR {#sec4.3.6}

RNA isolation was performed using Trizol Reagent (Sigma T9424). Reverse transcription was performed using the High-Capacity cDNA Reverse Transcription kit (Applied Biosystems 4368814), following the manufacturer's recommendations. qPCR was performed using the PowerUp SYBR Green Master Mix (Applied Biosystems A25742) and ABI PRISM® 7900HT Sequence Detection System. The expression level of each gene was determined by using the absolute quantification standard curve method. All values were normalized with *Gapdh* as endogenous housekeeping gene.

The following primers (mouse) were used:NOS1-Fw: ACTGACACCCTGCACCTGAAGANOS1-Rv: GTGCGGACATCTTCTGACTTCCNOS2-Fw: CAGCTGGGCTGTACAAACCTTNOS2-Rv: CATTGGAAGTGAAGCGGTTCGNOS3-Fw: CCTCGAGTAAAGAACTGGGAAGTGNOS3-Rv: AACTTCCTTGGAAACACCAGGGGapdh-Fw: GCATGGCCTTCCGTGTTCGapdh-Rv: CTGCTTCACCACCTTCTTGAT

### ELISA {#sec4.3.7}

MILLIPLEX MAP Mouse Cytokine/Chemokine Magnetic Bead Panel (MCYTOMAG-70K, Merck Millipore) was performed following the manufacture's protocol. Extracellular fluids of mouse long bones were collected from the supernatants following BM extraction and subjected to the mouse cytokine panel.

### Measurement of nitrate concentration {#sec4.3.8}

NO(X) content was measured in freshly-thawed samples that had been kept at −80°C for less than 2 months using a nitric oxide analyzer (NOA) 280i (Siever, GE Healthcare) according to the manufacturer's instructions. Data were collected, processed and analyzed by using liquid software (Siever, GE Healthcare).

### Statistical analyses {#sec4.3.9}

Statistical analyses and graphics were carried out with GraphPad Prism 5 software and Microsoft Excel.

Data and Code Availability {#sec4.4}
--------------------------
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